$TVTX
Travere Therapeutics, Inc.

2022 Q4 Form 10-Q Financial Statement

#000143853322000051 Filed on October 27, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $55.87M $53.50M
YoY Change -2.41% -21.58%
Cost Of Revenue $1.728M $1.675M
YoY Change -8.86% 5.21%
Gross Profit $54.14M $51.82M
YoY Change -2.19% -22.22%
Gross Profit Margin 96.91% 96.87%
Selling, General & Admin $56.60M $57.52M
YoY Change 57.86% 59.49%
% of Gross Profit 104.54% 111.0%
Research & Development $57.79M $59.26M
YoY Change -6.61% 22.41%
% of Gross Profit 106.73% 114.35%
Depreciation & Amortization $9.301M $8.578M
YoY Change 53.74% 8.95%
% of Gross Profit 17.18% 16.55%
Operating Expenses $121.0M $116.8M
YoY Change 17.99% 38.24%
Operating Profit -$66.85M -$68.13M
YoY Change 41.66% 114.86%
Interest Expense $219.0K -$2.892M
YoY Change -104.53% -40.97%
% of Operating Profit
Other Income/Expense, Net $872.0K -$1.377M
YoY Change 92.07% -64.56%
Pretax Income -$65.76M -$69.51M
YoY Change 27.52% 95.28%
Income Tax $63.00K $145.0K
% Of Pretax Income
Net Earnings -$65.82M -$69.66M
YoY Change 27.63% 95.45%
Net Earnings / Revenue -117.82% -130.21%
Basic Earnings Per Share -$1.03 -$1.09
Diluted Earnings Per Share -$1.03 -$1.09
COMMON SHARES
Basic Shares Outstanding 64.17M shares 63.96M shares
Diluted Shares Outstanding 64.03M shares

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $347.2M $448.1M
YoY Change -18.86% -1.04%
Cash & Equivalents $61.69M $151.3M
Short-Term Investments $285.5M $296.8M
Other Short-Term Assets $12.62M $8.549M
YoY Change 95.09% 13.93%
Inventory $6.922M $7.297M
Prepaid Expenses
Receivables $16.65M $12.70M
Other Receivables $0.00 $0.00
Total Short-Term Assets $486.4M $534.8M
YoY Change -16.54% -7.64%
LONG-TERM ASSETS
Property, Plant & Equipment $9.049M $9.557M
YoY Change -18.52% -16.99%
Goodwill $900.0K $900.0K
YoY Change 0.0% -3.85%
Intangibles $145.0M $149.5M
YoY Change -2.29%
Long-Term Investments
YoY Change
Other Assets $11.06M $11.09M
YoY Change -0.07% -68.19%
Total Long-Term Assets $186.1M $191.4M
YoY Change -3.95% -2.36%
TOTAL ASSETS
Total Short-Term Assets $486.4M $534.8M
Total Long-Term Assets $186.1M $191.4M
Total Assets $672.6M $726.2M
YoY Change -13.4% -6.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $17.29M $14.01M
YoY Change 14.17% 140.31%
Accrued Expenses $95.74M $88.38M
YoY Change 27.35% 39.61%
Deferred Revenue $11.98M $11.38M
YoY Change -26.38% -29.16%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $142.2M $131.0M
YoY Change 14.57% 15.79%
LONG-TERM LIABILITIES
Long-Term Debt $375.5M $375.1M
YoY Change 65.74% 67.69%
Other Long-Term Liabilities $9.385M $9.304M
YoY Change -23.55% -78.49%
Total Long-Term Liabilities $9.385M $9.304M
YoY Change -23.55% -78.49%
TOTAL LIABILITIES
Total Short-Term Liabilities $142.2M $131.0M
Total Long-Term Liabilities $9.385M $9.304M
Total Liabilities $629.7M $625.5M
YoY Change 32.71% 33.75%
SHAREHOLDERS EQUITY
Retained Earnings -$1.014B -$948.4M
YoY Change 32.41% 32.76%
Common Stock $6.000K $6.000K
YoY Change 0.0% -100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $42.85M $100.7M
YoY Change
Total Liabilities & Shareholders Equity $672.6M $726.2M
YoY Change -13.4% -6.3%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income -$65.82M -$69.66M
YoY Change 27.63% 95.45%
Depreciation, Depletion And Amortization $9.301M $8.578M
YoY Change 53.74% 8.95%
Cash From Operating Activities -$54.64M -$39.53M
YoY Change 103.3% -223.27%
INVESTING ACTIVITIES
Capital Expenditures $4.197M -$7.633M
YoY Change -180.71% 42.04%
Acquisitions
YoY Change
Other Investing Activities -$32.50M $17.71M
YoY Change -358.58% -53.26%
Cash From Investing Activities -$36.70M $10.08M
YoY Change -597.98% -69.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 551.0K 2.278M
YoY Change -98.34% -5.63%
NET CHANGE
Cash From Operating Activities -54.64M -39.53M
Cash From Investing Activities -36.70M 10.08M
Cash From Financing Activities 551.0K 2.278M
Net Change In Cash -90.79M -27.17M
YoY Change -762.41% -140.55%
FREE CASH FLOW
Cash From Operating Activities -$54.64M -$39.53M
Capital Expenditures $4.197M -$7.633M
Free Cash Flow -$58.84M -$31.89M
YoY Change 171.43% -185.19%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Entity Central Index Key
EntityCentralIndexKey
0001438533
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2021 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006CumulativeEffectPeriodOfAdoptionMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36257
dei Entity Registrant Name
EntityRegistrantName
TRAVERE THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-4842691
dei Entity Address Address Line1
EntityAddressAddressLine1
3611 Valley Centre Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
dei City Area Code
CityAreaCode
888
dei Local Phone Number
LocalPhoneNumber
969-7879
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
TVTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
64173570 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
151337000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
165753000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
354989000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
387129000 usd
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
12670000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15914000 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
7297000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
7313000 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8549000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6718000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
534842000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
582827000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9557000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11106000 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
21253000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
23196000 usd
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
149469000 usd
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
148435000 usd
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11094000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11069000 usd
CY2022Q3 us-gaap Assets
Assets
726215000 usd
CY2021Q4 us-gaap Assets
Assets
776633000 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
14010000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
15144000 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
88383000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
75180000 usd
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
11383000 usd
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
16268000 usd
CY2022Q3 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
7300000 usd
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
7400000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4233000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3908000 usd
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5723000 usd
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
6188000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
131032000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
124088000 usd
CY2022Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
375117000 usd
CY2021Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
226581000 usd
CY2022Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
12919000 usd
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
20379000 usd
CY2022Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
68900000 usd
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
59700000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28267000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
31497000 usd
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
9304000 usd
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
12276000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
625539000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
474521000 usd
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
64150510 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
64150510 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62491498 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62491498 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
6000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
6000 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1048767000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1068634000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-948400000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-765966000 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
303000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-562000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
100676000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
302112000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
726215000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
776633000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
53496000 usd
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
68217000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
156150000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
170241000 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1675000 usd
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1592000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5864000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4888000 usd
CY2022Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
59256000 usd
CY2021Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
48407000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
175548000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
148160000 usd
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
57519000 usd
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
36065000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
157286000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
107808000 usd
CY2022Q3 tvtx Changein Fair Valueof Contingent Consideration
ChangeinFairValueofContingentConsideration
3180000 usd
CY2021Q3 tvtx Changein Fair Valueof Contingent Consideration
ChangeinFairValueofContingentConsideration
13864000 usd
tvtx Changein Fair Valueof Contingent Consideration
ChangeinFairValueofContingentConsideration
17167000 usd
tvtx Changein Fair Valueof Contingent Consideration
ChangeinFairValueofContingentConsideration
23960000 usd
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
121630000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
4083000 usd
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
99928000 usd
us-gaap Costs And Expenses
CostsAndExpenses
355865000 usd
us-gaap Costs And Expenses
CostsAndExpenses
284816000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-68134000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-31711000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-199715000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-114575000 usd
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2101000 usd
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
360000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
3161000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
1757000 usd
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-2892000 usd
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-4899000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-8379000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-15072000 usd
CY2022Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2021Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-7578000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-586000 usd
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
654000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
102000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-223000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1377000 usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3885000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-12694000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-13538000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-69511000 usd
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35596000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-212409000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-128113000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
145000 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
43000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
250000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
405000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-69656000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-35639000 usd
us-gaap Net Income Loss
NetIncomeLoss
-212659000 usd
us-gaap Net Income Loss
NetIncomeLoss
-128518000 usd
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.09
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.17
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64033759 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64033759 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60803045 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60803045 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63604962 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63604962 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59230881 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59230881 shares
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-69656000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-35639000 usd
us-gaap Net Income Loss
NetIncomeLoss
-212659000 usd
us-gaap Net Income Loss
NetIncomeLoss
-128518000 usd
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
2596000 usd
CY2021Q3 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
216000 usd
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
4083000 usd
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
1091000 usd
CY2022Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-1211000 usd
CY2021Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-100000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-3218000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-714000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-68271000 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35523000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-211794000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-128141000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
156713000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
332303000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
8464000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
6757000 usd
CY2022Q3 us-gaap Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
3408000 usd
CY2021Q3 us-gaap Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
3605000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
362000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
228000 usd
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
2596000 usd
CY2021Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
216000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1211000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-100000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-69656000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-35639000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
100676000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
307370000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
302112000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
211213000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
28751000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
21524000 usd
us-gaap Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
4354000 usd
us-gaap Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
6679000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2428000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1938000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1091000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-3218000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-714000 usd
us-gaap Net Income Loss
NetIncomeLoss
-212659000 usd
us-gaap Net Income Loss
NetIncomeLoss
-128518000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
100676000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
307370000 usd
us-gaap Net Income Loss
NetIncomeLoss
-212659000 usd
us-gaap Net Income Loss
NetIncomeLoss
-128518000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
29649000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
22190000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
23778000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
20567000 usd
us-gaap Nature Of Operations
NatureOfOperations
DESCRIPTION OF BUSINESS<div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Organization and Description of Business</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Travere Therapeutics, Inc. (“we”, “our”, “us”, “Travere” and the “Company”) refers to Travere Therapeutics, Inc., a Delaware corporation, as well as our direct and indirect subsidiaries. Travere is a fully integrated biopharmaceutical company headquartered in San Diego, California focused on identifying, developing and delivering life-changing therapies to people with rare diseases. We regularly evaluate and, where appropriate, act on opportunities to expand our product pipeline through licenses and acquisitions of products in areas that will serve patients with serious or rare diseases and that we believe offer attractive growth characteristics. </span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The ongoing novel coronavirus (COVID-19) pandemic has resulted in travel restrictions, quarantines, “stay-at-home” and “shelter-in-place” orders and extended shutdown of certain businesses around the world. While the impact of the COVID-19 pandemic did not have a material adverse effect on our financial position or results of operations for the nine months ended September 30, 2022, these governmental actions and similar actions that may be enacted in the future, and the widespread economic disruption arising from the pandemic, have the potential to materially impact our business and influence our business decisions. The extent and duration of the pandemic is unknown, and the future effects on our business are uncertain and difficult to predict. The Company is continuing to monitor the events and circumstances surrounding the COVID-19 pandemic, which may require adjustments to the Company’s estimates and assumptions in the future.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Programs:</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sparsentan is a novel investigational product candidate and has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerois (FSGS) and immunoglobulin A nephropathy (IgAN) in the U.S. and Europe. Sparsentan is currently being evaluated in two pivotal Phase 3 clinical studies in rare kidney diseases.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pegtibatinase (</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">TVT-058) is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU). Pegtibatinase has been granted Rare Pediatric Disease, Fast Track and Breakthrough Therapy designations by the FDA, as well as orphan drug designation in the United States and European Union. Pegtibatinase is currently being evaluated in the Phase 1/2 COMPOSE Study to assess its safety, tolerability, pharmacokinetics, pharmacodynamics and clinical effects in patients with classical HCU. The Company</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> acquired pegtibatinase as part of the November 2020 acquisition of Orphan Technologies Limited.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Chenodal (chenodeoxycholic acid or CDCA) is a naturally occurring bile acid that is approved for the treatment of people with radiolucent stones in the gallbladder. In January 2020, we randomized the first patients in our Phase 3 RESTORE Study to evaluate the effects of Chenodal in adult and pediatric patients with cerebrotendinous xanthomatosis (CTX), and the study enrollment remains open. The pivotal study is intended to support an NDA submission for marketing authorization of Chenodal for CTX in the United States. </span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical Programs:</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is a participant in a Cooperative Research and Development Agreement ("CRADA"), which forms a multi-stakeholder approach to pool resources with leading experts, and incorporate the patient perspective early in the therapeutic identification and development process. The Company is partnering with the National Institutes of Health’s National Center for Advancing Translational Sciences ("NCATS") and a leading patient advocacy organization, Alagille Syndrome Alliance, aimed at the identification of potential small molecule therapeutics for Alagille syndrome ("ALGS"). There are no treatment options currently approved for ALGS. The Company is no longer pursuing the identification of potential small molecule therapeutics for NGLY1 deficiency.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Approved products:</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:15.42pt">Chenodal (chenodiol tablets) is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. </span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:15.42pt">Cholbam</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (cholic acid capsules) is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders.</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:15.42pt">Thiola</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and Thiola EC</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (tiopronin tablets) are approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.</span></div>
tvtx Net Changein Fair Valueof Contingent Consideration
NetChangeinFairValueofContingentConsideration
17167000 usd
tvtx Net Changein Fair Valueof Contingent Consideration
NetChangeinFairValueofContingentConsideration
23960000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-6449000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-5675000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1194000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
8356000 usd
us-gaap Inventory Write Down
InventoryWriteDown
2070000 usd
us-gaap Inventory Write Down
InventoryWriteDown
1372000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-7578000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-3658000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-5028000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3264000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2577000 usd
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
396000 usd
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-17006000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2053000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
380000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1562000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2045000 usd
tvtx Change In Lease Assets And Liabilities Net
ChangeInLeaseAssetsAndLiabilitiesNet
-738000 usd
tvtx Change In Lease Assets And Liabilities Net
ChangeInLeaseAssetsAndLiabilitiesNet
5823000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-364000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4325000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
15229000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
6233000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-8898000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
40153000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-2119000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-237000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-131651000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
12085000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
329612000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
376099000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
301104000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
502141000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
161000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4947000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
24199000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
14004000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4148000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-144993000 usd
tvtx Payment Of Guaranteed Minimum Royalty
PaymentOfGuaranteedMinimumRoyalty
1575000 usd
tvtx Payment Of Guaranteed Minimum Royalty
PaymentOfGuaranteedMinimumRoyalty
1575000 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
1875000 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
2065000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
316250000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
9882000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
211324000 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4354000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6679000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1529000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1275000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
117022000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
198470000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-3935000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-7000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14416000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
65555000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
165753000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84772000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
151337000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
150327000 usd
CY2022Q3 tvtx Number Of Phase3 Clinical Trials In Process
NumberOfPhase3ClinicalTrialsInProcess
3 clinical_trial
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3680000 usd
us-gaap Revenue Performance Obligation Description Of Timing
RevenuePerformanceObligationDescriptionOfTiming
The Company receives payments from its product sales based on terms that generally are within 30 days of delivery of product to the patient.
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
329600000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
301100000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
354989000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
354989000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
387129000 usd
CY2022Q3 tvtx Debt Securities Availableforsale Amortized Cost Basis Current
DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent
299378000 usd
CY2022Q3 tvtx Debt Securities Available For Sale Unrealized Gain Current
DebtSecuritiesAvailableForSaleUnrealizedGainCurrent
0 usd
CY2022Q3 tvtx Debt Securities Available For Sale Unrealized Loss Current
DebtSecuritiesAvailableForSaleUnrealizedLossCurrent
2625000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
296753000 usd
CY2022Q3 tvtx Debt Securities Availableforsale Amortized Cost Basis Noncurrent
DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent
59291000 usd
CY2022Q3 tvtx Debt Securities Available For Sale Unrealized Gain Noncurrent
DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent
0 usd
CY2022Q3 tvtx Debt Securities Available For Sale Unrealized Loss Noncurrent
DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent
1055000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
58236000 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
358669000 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2021Q4 tvtx Debt Securities Availableforsale Amortized Cost Basis Current
DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent
262345000 usd
CY2021Q4 tvtx Debt Securities Available For Sale Unrealized Gain Current
DebtSecuritiesAvailableForSaleUnrealizedGainCurrent
0 usd
CY2021Q4 tvtx Debt Securities Available For Sale Unrealized Loss Current
DebtSecuritiesAvailableForSaleUnrealizedLossCurrent
159000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
262186000 usd
CY2021Q4 tvtx Debt Securities Availableforsale Amortized Cost Basis Noncurrent
DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent
125254000 usd
CY2021Q4 tvtx Debt Securities Available For Sale Unrealized Gain Noncurrent
DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent
0 usd
CY2021Q4 tvtx Debt Securities Available For Sale Unrealized Loss Noncurrent
DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent
311000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
124943000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
387599000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
470000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
387129000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
292606000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
3175000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
62383000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
505000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
354989000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
3680000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
380690000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
470000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
380690000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
470000 usd
CY2022Q3 tvtx Debt Securities Available For Sale Unrealized Loss Position Amortized Cost
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCost
358700000 usd
CY2021Q4 tvtx Debt Securities Available For Sale Unrealized Loss Position Amortized Cost
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCost
381200000 usd
CY2019Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2019Q2 tvtx Lessee Operating Lease Aggregate Liability
LesseeOperatingLeaseAggregateLiability
49500000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
3700000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1513000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6200000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
6386000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
6578000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
6775000 usd
CY2022Q3 tvtx Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
11760000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
39212000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6712000 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
32500000 usd
CY2022Q3 tvtx Operating Lease Incentive Tenant Improvements
OperatingLeaseIncentiveTenantImprovements
5820000 usd
CY2022Q3 tvtx Straight Line Lease Expense In Excess Of Cash Payments
StraightLineLeaseExpenseInExcessOfCashPayments
5427000 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
21253000 usd
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1200000 usd
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1200000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
3600000 usd
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
552882000 usd
us-gaap Number Of Businesses Acquired
NumberOfBusinessesAcquired
2 business
CY2022Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
151337000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
354989000 usd
CY2022Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
506326000 usd
CY2022Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
76200000 usd
CY2022Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
76200000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
165753000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
387129000 usd
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
67100000 usd
CY2021Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
67100000 usd
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
67100000 usd
tvtx Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Change In Fair Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue
17167000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
5387000 usd
tvtx Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements Accrued
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsAccrued
2680000 usd
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
76200000 usd
CY2022Q3 tvtx Changein Fair Valueof Contingent Consideration
ChangeinFairValueofContingentConsideration
3200000 usd
tvtx Changein Fair Valueof Contingent Consideration
ChangeinFairValueofContingentConsideration
17200000 usd
CY2021Q3 tvtx Changein Fair Valueof Contingent Consideration
ChangeinFairValueofContingentConsideration
13900000 usd
tvtx Changein Fair Valueof Contingent Consideration
ChangeinFairValueofContingentConsideration
24000000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
148500000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
18432000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
306787000 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
283557000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
158254000 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
136058000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
148533000 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
147499000 usd
CY2021Q4 us-gaap Goodwill
Goodwill
900000 usd
CY2022Q3 us-gaap Goodwill
Goodwill
900000 usd
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
8069000 usd
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
6344000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
22196000 usd
CY2022Q1 tvtx Debt Instrument Repurchase Amount Including Accrued And Unpaid Interest
DebtInstrumentRepurchaseAmountIncludingAccruedAndUnpaidInterest
213800000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-7600000 usd
us-gaap Write Off Of Deferred Debt Issuance Cost
WriteOffOfDeferredDebtIssuanceCost
3400000 usd
CY2022Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
29981000 usd
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
25998000 usd
CY2022Q3 tvtx Accrued Liabilities Researchand Development Current
AccruedLiabilitiesResearchandDevelopmentCurrent
27962000 usd
CY2021Q4 tvtx Accrued Liabilities Researchand Development Current
AccruedLiabilitiesResearchandDevelopmentCurrent
26841000 usd
CY2022Q3 tvtx Government Rebates Payable
GovernmentRebatesPayable
13366000 usd
CY2021Q4 tvtx Government Rebates Payable
GovernmentRebatesPayable
7493000 usd
CY2022Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
7449000 usd
CY2021Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
8402000 usd
CY2022Q3 tvtx Accrued Liabilities Selling Generaland Administrative Current
AccruedLiabilitiesSellingGeneralandAdministrativeCurrent
7235000 usd
CY2021Q4 tvtx Accrued Liabilities Selling Generaland Administrative Current
AccruedLiabilitiesSellingGeneralandAdministrativeCurrent
3144000 usd
CY2022Q3 tvtx Accrued Liabilities Miscellaneous
AccruedLiabilitiesMiscellaneous
2390000 usd
CY2021Q4 tvtx Accrued Liabilities Miscellaneous
AccruedLiabilitiesMiscellaneous
3302000 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
88383000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
75180000 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63604962 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63604962 shares
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-212659000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-212659000 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.34
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64033759 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64033759 shares
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-69656000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-69656000 usd
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.09
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60803045 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60803045 shares
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-35639000 usd
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-35639000 usd
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.34
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59230881 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59230881 shares
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-128518000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-128518000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.17
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24043806 shares
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17984802 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22751692 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18012120 shares
CY2022Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
857000 usd
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
255000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
5018000 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6800000 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
20.18
CY2022Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
4064000 usd
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
5205000 usd
CY2022Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2376000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8826000 usd
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6986000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
29649000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22190000 usd
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1853000 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
7297000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
7313000 usd
CY2022Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
4100000 usd
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
4100000 usd
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
12700000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15900000 usd
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares

Files In Submission

Name View Source Status
0001438533-22-000051-index-headers.html Edgar Link pending
0001438533-22-000051-index.html Edgar Link pending
0001438533-22-000051.txt Edgar Link pending
0001438533-22-000051-xbrl.zip Edgar Link pending
ex09302022311.htm Edgar Link pending
ex09302022312.htm Edgar Link pending
ex09302022321.htm Edgar Link pending
ex09302022322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tvtx-20220930.htm Edgar Link pending
tvtx-20220930.xsd Edgar Link pending
tvtx-20220930_g1.jpg Edgar Link pending
tvtx-20220930_cal.xml Edgar Link unprocessable
tvtx-20220930_def.xml Edgar Link unprocessable
tvtx-20220930_lab.xml Edgar Link unprocessable
tvtx-20220930_pre.xml Edgar Link unprocessable
tvtx-20220930_htm.xml Edgar Link completed